Blog
RSS FeedPosted by Michael Wonder on 04 Mar 2026
J&J Korea receives reimbursement for Balversa in urothelial carcinoma
3 March 2026 - Johnson & Johnson Innovative Medicine Korea said it received reimbursement for Balversa (erdafitinib), a treatment for ...
Posted by Michael Wonder on 02 Mar 2026
World first cheaper immunotherapy treatment listing for patients with advanced or rare cancers
1 March 2026 - From today, thousands more Australians living with advanced and rare cancers will have access to affordable ...
Posted by Michael Wonder on 01 Mar 2026
New PBS listing for immunotherapy cancer drugs Opdivo and Yervoy to be slashed
2 March 2026 - Patients with advanced and rare cancers will be able to access two immunotherapy drugs for just $25, ...
Posted by Michael Wonder on 28 Feb 2026
Ontario becomes the first province to publicly reimburse the first targeted oral therapy for adults with grade 2 IDH-mutant glioma
27 February 2026 - Servier Canada announces Ontario coverage of Voranigo under the FAST program. ...
Posted by Michael Wonder on 27 Feb 2026
Enhertu supplemental new drug application submitted in Japan as adjuvant therapy for patients with HER2 positive early breast cancer
27 February 2026 - Submission based on DESTINY-Breast05 phase 3 trial results, which showed Enhertu reduced the risk of invasive ...
Posted by Michael Wonder on 26 Feb 2026
FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer
26 February 2026 - Today, the FDA granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals), a kinase inhibitor, for ...
Posted by Michael Wonder on 25 Feb 2026
MHRA approves imlunestrant tosylate (Inluryo) - a new treatment for breast cancer
24 February 2026 - The MHRA has today approved imlunestrant tosylate (Inluriyo), a new treatment for adult patients with a ...
Posted by Michael Wonder on 25 Feb 2026
Siren Biotechnology receives FDA fast track designation for SRN-101 for the treatment of recurrent high grade glioma
24 February 2026 - Siren Biotechnology today announced that the US FDA has granted fast track designation to SRN-101, the ...
Posted by Michael Wonder on 25 Feb 2026
Aktis Oncology receives US FDA fast track designation for AKY-1189, a nectin-4 miniprotein radioconjugate
24 February 2026 - Aktis Oncology today announced that the US FDA has granted fast track designation to AKY-1189 for the ...
Posted by Michael Wonder on 24 Feb 2026
FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation
24 February 2026 - Today, the FDA granted traditional approval to encorafenib (Braftovi, Array BioPharma, a subsidiary of Pfizer) in ...
Posted by Michael Wonder on 24 Feb 2026
PHARMAC proposes to widen access to two medicines for people with melanoma
24 February 2026 - PHARMAC is proposing to widen access to two medicines used to treat melanoma, giving people another ...
Posted by Michael Wonder on 24 Feb 2026
Artios receives US FDA fast track designation for DNA polymerase theta inhibitor ART6043 for treatment of gBRCA-mutated HER2 negative breast cancer
23 February 2026 - Artios Pharma today announced that the US FDA granted fast track designation to its potentially first ...
Posted by Michael Wonder on 21 Feb 2026
FDA accepts new drug application for Roche’s giredestrant in ESR1 mutated, ER positive advanced breast cancer
20 February 2026 - Roche announced today that the US FDA has accepted the company’s new drug application for giredestrant, an ...
Posted by Michael Wonder on 21 Feb 2026
FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukaemia or small lymphocytic lymphoma
20 February 2026 - On 19 February 2026, the FDA approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax ...
Posted by Michael Wonder on 20 Feb 2026
Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukaemia in the 1st-line setting
20 February 2026 - Calquence plus venetoclax demonstrated statistically significant and clinically meaningful improvement in progression-free survival versus chemoimmunotherapy, with 77% ...